EP3098224B1 - Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease - Google Patents

Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease Download PDF

Info

Publication number
EP3098224B1
EP3098224B1 EP14873860.2A EP14873860A EP3098224B1 EP 3098224 B1 EP3098224 B1 EP 3098224B1 EP 14873860 A EP14873860 A EP 14873860A EP 3098224 B1 EP3098224 B1 EP 3098224B1
Authority
EP
European Patent Office
Prior art keywords
branched
compound
straight
benzyloxy
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14873860.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3098224A1 (en
EP3098224A4 (en
Inventor
Sang Ku Yoo
Jin Wook Chung
In Geun Jo
Jeong Ho Im
Ku Suk Kang
Jin Young Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaceum Inc
Original Assignee
Glaceum Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaceum Inc filed Critical Glaceum Inc
Priority to PL14873860T priority Critical patent/PL3098224T3/pl
Publication of EP3098224A1 publication Critical patent/EP3098224A1/en
Publication of EP3098224A4 publication Critical patent/EP3098224A4/en
Application granted granted Critical
Publication of EP3098224B1 publication Critical patent/EP3098224B1/en
Priority to HRP20190573TT priority patent/HRP20190573T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Definitions

  • One or more exemplary embodiments relate to a novel pyranochromenylphenol derivative which is effective for preventing or treating a metabolic syndrome or an inflammatory disease, and the use thereof for preventing or treating a metabolic syndrome or an inflammatory disease.
  • a human body has approximately 20 billion or more adipocytes, and if supplies of energy are extremely excessive to demands thereon, triglycerides are stored in the adipocytes in the human body, which are degraded into free fatty acids and glucose, which will be used as an energy source upon the exhaustion of energy.
  • Obesity which about 30 to about 40% of people of today have, occurs when excessive energy is accumulated due to imbalance of the above process, and shows the increased size and number of adipocytes.
  • the hygienic environment has been improved due to improvement in the standard of living resulting from the recent economic development, frequent consumption of instant food products and changes in dietary habits toward the consumption of more meat induce the accumulation of excessive amounts of caloric energy in the body.
  • These changes in dietary habits of people of today show a tendency of a rapid increase in the obese population in addition to a decrease in consumption of calories due to the lack of exercise. This obesity is so closely associated with a metabolic syndrome that obesity may be used for the diagnosis of a metabolic syndrome.
  • the metabolic syndrome is a term used to conceptualize a cluster of risk factors of various cardiovascular diseases and type 2 diabetes mellitus as one disease group. This is a useful concept which may comprehensively explain all of the insulin resistance and complex and various metabolic disorders and clinical aspects associated with the same, and refers to a syndrome in which risk factors such as obesity, diabetes, fatty liver and hypertriglyceridemia are together increased. Accordingly, when a person gets a metabolic syndrome, the risk of developing a cardiovascular disease or type 2 diabetes mellitus is increased.
  • Insulin resistance refers to a phenomenon in which even though insulin is normally secreted in vivo, insulin does not induce sufficient supply of glucose to cells. Therefore, glucose in the blood cannot enter cells, thus causing hyperglycemia, and thereby cells cannot perform normal functions due to a shortage of glucose, leading to the manifestation of a metabolic syndrome.
  • the diabetic symptoms thus developed are classified into type 2 diabetes mellitus (T2DM, noninsulin-dependent diabetes mellitus: NIDDM), which is different from type 1 diabetes mellitus (insulin-dependent diabetes mellitus). For this reason, the most preferred method of treating type 2 diabetes mellitus is to induce insulin so as to perform normal functions by improving insulin resistance. Nevertheless, an agent for improving insulin resistance has been scarcely developed so far.
  • Patent Document 1 discloses the use of glabridin for preventing or treating a metabolic syndrome including hyperlipidemia, fatty liver, glucose metabolism disorder, diabetes and obesity:
  • Glabridin is known to be effective not only for a metabolic syndrome including hyperlipidemia, fatty liver, glucose metabolism disorder, diabetes and obesity, but also for prevention and treatment such as anti-inflammatory action and anticancer action, but is easily broken down by sunlight, moisture, acidity, basicity, oxygen, heat and the like due to low chemical stability, so that it is very difficult to develop a product utilizing glabridin (Non-Patent Document 1).
  • leptin resistance and insulin resistance are each considered to be an important cause for obesity and type 2 diabetes mellitus (T2DM), and the most representative and inventive mechanism causing these resistances is due to a problem caused during the signaling process in a leptin receptor and an insulin receptor (IR), and both the receptors are commonly closely associated with protein tyrosine phosphatase 1B (PTP1B) (Non-Patent Document 2).
  • a PTP1B inhibitor which may arbitrarily control the activity of PTP1B, is highly likely to be developed as a therapeutic agent for obesity and type 2 diabetes mellitus, which normalizes the activity of leptin and insulin by alleviating leptin and insulin resistance (Non-Patent Documents 3 and 4).
  • PTP1B is closely associated with not only obesity and diabetes, but also various inflammatory diseases, heart diseases, endoplasmic reticulum stress diseases, breast cancer, prostate cancer and the like.
  • various chronic diseases referred to as adult diseases in a typical sense are directly and indirectly associated with PTP1B
  • PTP1B has been highlighted as an important and fundamental therapeutic target for treating these adult diseases. In this sense, it is not too much to say that PTP1B is the most basic and fundamental cause of disease, which forms the bottom of many adult diseases (Non-Patent Document 5).
  • One or more exemplary embodiments include a new pyranochromenylphenol derivative which is excellent in anti-obesity efficacy, antidiabetic efficacy, and anti-inflammatory efficacy, and is not only effective for treatment of hyperlipidemia and the like, but also chemically stable even under acidic or basic conditions as well as general atmospheric conditions which include oxygen.
  • One or more exemplary embodiments include a pharmaceutical composition for preventing or treating a metabolic syndrome or an inflammatory disease.
  • a pharmaceutical composition for use in preventing or treating a metabolic syndrome or an inflammatory disease includes a compound of the following Formula (I'), a pharmaceutically acceptable salt thereof, or a solvate thereof: in the formula,
  • a pharmaceutical composition including the pyranochromenylphenol according to one exemplary embodiment of the present invention is effective for treating or preventing a metabolic syndrome or an inflammatory disease, and is chemically stable.
  • a pyranochromenylphenol derivative according to an aspect of the present invention may be represented by the following Formula (I): in the formula,
  • the pyranochromenylphenol derivative according to an exemplary embodiment of the present invention has an excellent effect in preventing or treating a metabolic syndrome such as obesity, diabetes, hyperlipidemia, and fatty liver, or an inflammatory disease, and simultaneously has an excellent effect even in terms of chemical stability.
  • R 1 is a hydrogen atom
  • R 2 may be methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, 2-methoxyethyl, trifluoromethyl, fluoro, chloro, bromo, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, n-pentoxy, methoxymethoxy, and the like.
  • R 1 in Formula (I) when R 1 in Formula (I) is a halogen atom, the halogen atom may be fluoro, chloro, or bromo.
  • the compound of Formula (I) may be one or more of the following compounds.
  • Compound 14 is only a reference compound.
  • the pharmaceutically acceptable salt may be present as an acid addition salt formed by the compound of Formula (I) and a free acid.
  • the compound of Formula (I) may form a pharmaceutically acceptable acid addition salt by a typical method publicly known in the art.
  • an organic acid or an inorganic acid may be used, and as the inorganic acid, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, and the like may be used, and as the organic acid, it is possible to use citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluene sulfonic acid, galacturonic acid, embonic acid, glutamic acid, aspartic acid, and the like.
  • the pharmaceutically acceptable salt may be present as an inorganic salt of the compound of Formula (I).
  • the compound of Formula (I) may form a pharmaceutically acceptable inorganic salt by a typical method publicly known in the art.
  • the inorganic salt include salts with aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, or zinc, but the present invention is not limited to, and ammonium, calcium, magnesium, potassium or sodium salt is preferred.
  • a method of preparing the compound of Formula (I) is not particularly limited, but the compound may be prepared based on a synthesis method of ( ⁇ )-glabridin developed by the present inventor(s) ( Bull. Korean Chem. Soc. 2007 (28) 481 ⁇ 484 ).
  • OBz is a benzoyloxy group
  • Me is a methyl group
  • R 1 and R 2 are the same as those defined above
  • P means a protecting group such as a benzyl group, a methoxymethyl group, and a trialkylsilyl group
  • DEAD represents diethyl azodicarboxylate.
  • P is a benzyl group
  • a deprotection group process simultaneously proceeds during the hydrogenation reaction without a separate deprotection process.
  • a pharmaceutical composition for preventing or treating a metabolic syndrome or inflammatory disease includes a compound of the following Formula (I'), pharmaceutically acceptable salts thereof, or solvates thereof. in the formula,
  • R1 is a hydrogen atom
  • R 2 may be a hydrogen atom; a hydroxy group; a substituted or unsubstituted straight or branched C 1 -C 5 alkyl group; a straight or branched C 1 -C 5 alkoxy group; or a straight or branched C 1 -C 4 thioalkyl group.
  • R 1 is a hydrogen atom
  • R 2 may be methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, 2-methoxyethyl, trifluoromethyl, fluoro, chloro, bromo, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, n-pentoxy, methoxymethoxy, and the like.
  • R 1 in Formula (I') when R 1 in Formula (I') is a halogen atom, the halogen atom may be fluoro, chloro, or bromo.
  • the compound of Formula (I') may be one or more of the following compounds.
  • the metabolic syndrome may be one or more of obesity, diabetes, hyperlipidemia, and fatty liver. Further, the diabetes may be type 2 diabetes mellitus (T2DM).
  • T2DM type 2 diabetes mellitus
  • the metabolic syndrome may be a complex disease of type 2 diabetes mellitus and obesity.
  • the term 'metabolic syndrome' refers to a disease of which the risk increases at the time of getting the metabolic syndrome, and refers to a disease of which the risk factor such as, for example, hypertriglyceridemia, fatty liver, diabetes, and obesity increases, but the present invention is not limited thereto.
  • the pharmaceutical composition according to an exemplary embodiment of the present invention may prevent or treat the complex disease of type 2 diabetes mellitus and obesity, and thus is very ideal.
  • the inflammatory disease may be one or more of rheumatoid arthritis; degenerative arthritis; and inflammatory diseases occurring from asthma, atopy, diabetes, or myocardial infarction.
  • the pharmaceutical composition may be formulated into a typical pharmaceutical dosage form.
  • the dosage form includes orally administered preparations, injection preparations, suppositories, transdermally administered preparations, and nasally administered preparations, but may also be formulated into any dosage form which is not limited thereto.
  • the dosage form may be preferably formulated into a preparation for oral administration and an injection preparation.
  • the dosage form may be prepared by adding a pharmaceutically acceptable carrier which is necessary for preparation of each dosage form.
  • a pharmaceutically acceptable carrier is used to refer to any constituent ingredient except for pharmaceutically active ingredients.
  • pharmaceutically acceptable refers to the properties not to cause any pharmaceutically undesirable change via interaction between other constituent ingredients present in the composition (for example, via interaction between carriers or via interaction between the pharmaceutically active ingredient and a carrier). Selection of the pharmaceutically acceptable carrier may be dependent on factors such as the properties and the administration method of a particular dosage form and the effects of the carrier on solubility and stability.
  • the pharmaceutically acceptable carrier included in the oral pharmaceutical composition may be one or more selected from a diluent, a binder, a glidant (or a lubricant), a disintegrant, a stabilizer, a solubilizing agent, a sweetener, a coloring agent, and a flavoring agent, but is not limited thereto.
  • the diluent refers to any excipient added to increase the volume of the composition to formulate the composition into a target dosage form with an appropriate size.
  • starch for example, potato starch, corn starch, wheat starch, and pregelatinized starch
  • microcrystalline cellulose for example, low-hydrated microcrystalline cellulose
  • lactose for example, lactose monohydrate, anhydrous lactose, and spray lactose
  • glucose sorbitol, mannitol, sucrose, alginate, alkaline earth metal salts, clay, polyethylene glycol, dicalcium phosphate, anhydrous calcium hydrogenphosphate, silicon dioxide, and the like either alone or as a mixture thereof, but the diluent is not limited thereto.
  • the excipient may be used in a range of about 5 wt% to about 50 wt% based on a total weight of the pharmaceutical composition, and may be used in an amount of, for example, about 10 wt% to about 35 wt% based on the total weight of the pharmaceutical composition for tabletting and quality maintenance.
  • the binder refers to a material used to impart adhesiveness to materials in powder form to facilitate compression of the materials, and improve fluidity.
  • the binder may be one or more selected from starch, microcrystalline cellulose, highly dispersible silica, mannitol, lactose, polyethylene glycol, polyvinylpyrrolidone, cellulose derivatives (for example, hydroxypropyl methylcellulose, hydroxypropyl cellulose, or low-substituted hydroxypropyl cellulose), natural gum, synthetic gum, povidone, co-povidone, and gelatin, but is not limited thereto.
  • the binder may be used in an amount of about 2 wt% to about 15 wt% based on a total weight of the pharmaceutical composition, and may be used in an amount of, for example, about 1 wt% to about 3 wt% based on the total weight of the pharmaceutical composition for tabletting and quality maintenance.
  • the disintegrant refers to a material added to facilitate collapse or disintegration of a solid dosage form after administrated into the body.
  • starch such as sodium starch glycolate, corn starch, potato starch, or pregelatinized starch or modified starch
  • clay such as bentonite, montmorillonite, or veegum
  • cellulose such as microcrystalline cellulose, hydroxypropyl cellulose, or carboxymethyl cellulose
  • algins such as sodium alginate or alginic acid
  • a cross-linked cellulose such as croscarmellose sodium
  • gum such as guar gum or xanthan gum
  • a cross-linked polymer such as cross-linked polyvinylpyrrolidone (crospovidone); or an effervescent ingredient such as sodium bicarbonate or citric acid, either alone or as a mixture thereof, but the disintegrant is not limited thereto.
  • the disintegrant may be used in an amount of about 2 wt% to about 15 wt% based on a total weight of the pharmaceutical composition, and may be used in an amount of, for example, about 4 wt% to about 10 wt% based on the total weight of the pharmaceutical composition for tabletting and quality maintenance.
  • the glidant or lubricant refers to a material that prevents cohesion of powders to a compressing system and improves flowability of granules.
  • the glidant it is possible to use hard anhydrous silicic acid, talc, stearic acid, a metal salt (magnesium salt, calcium salt, or the like) of stearic acid, sodium lauryl sulfate, hydrogenated vegetable oil, sodium benzoate, sodium stearyl fumarate, glycerylbehenate, glycerylmonostearate, or polyethylene glycol, either alone or as a mixture thereof, but the glidant is not limited thereto.
  • the glidant may be used in an amount of about 0.1 wt% to about 5 wt% based on a total weight of the pharmaceutical composition, and may be used in an amount of, for example, about 1 wt% to about 3 wt% based on the total weight of the pharmaceutical composition for tabletting and quality maintenance.
  • adsorbent it is possible to use hydrated silicon dioxide, hard anhydrous silicic acid, colloidal silicon dioxide, magnesium aluminometasilicate, microcrystalline cellulose, lactose, or a cross-linked polyvinylpyrrolidone, either alone or as a mixture thereof, but the adsorbent is not limited thereto.
  • the stabilizer may be one or more selected from antioxidants, such as butylhydroxyanisol, butylhydroxytoluene, carotene, retinol, ascorbic acid, tocopherol, tocopherol polyethylene glycol succinic acid, or propyl gallate; cyclic sugar compounds such as cyclodextrin, carboxyethyl cyclodextrin, hydroxypropyl cyclodextrin, sulfobutylether, or cyclodextrin; and organic acids such as phosphoric acid, lactic acid, acetic acid, citric acid, tartaric acid, succinic acid, maleic acid, fumaric acid, glycolic acid, propionic acid, gluconic acid, or glucuronic acid, but is not limited thereto.
  • antioxidants such as butylhydroxyanisol, butylhydroxytoluene, carotene, retinol, ascorbic acid, tocopherol, tocopherol poly
  • an additive publicly known to improve the taste as well as mask the off-taste of the active ingredient may be included.
  • a sweetener such as sucralose, sucrose, fructose, erythritol, acesulfame potassium, sugar alcohol, honey, sorbitol, or aspartame may be added to more effectively mask bitterness and maintain the stability and quality of the preparation.
  • an acidifier such as citric acid or sodium citrate; a natural flavoring such as Japanese apricot flavor, lemon flavor, pineapple flavor, or herbal flavor; or a natural dye such as natural fruit juice, chlorophyllin, or flavonoid may be used.
  • the oral pharmaceutical composition may be a solid preparation, a semi-solid preparation or a liquid preparation for oral administration.
  • the solid preparation for oral administration include a tablet, a pill, a hard or soft capsule, a powder, a fine granule, a granule, a powder for reconstitution of solution or suspension, a lozenge, a wafer, an oral strip, a dragee, a chewable gum and the like for oral administration, but are not limited thereto.
  • the liquid preparation for oral administration includes solution, suspension, emulsion, syrup, elixir, spirit, aromatic waters, lemonade, extract, precipitant, tincture, and oily medicine.
  • the semi-solid preparation includes aerosol, cream, gel and the like, but is not limited thereto.
  • the pharmaceutical composition according to the present invention may be formulated into an injection preparation, and when the composition may be formulated into an injection preparation, the pharmaceutical composition according to the present invention may include a non-toxic buffer solution which is isotonic to a non-toxic buffer solution as a diluent, and examples thereof include a phosphoric acid buffer solution with a pH of 7.4, and the like.
  • the pharmaceutical composition may include other diluents or additives in addition to the buffer solution.
  • a method of preparing a carrier used in the aforementioned preparation and the preparation may be selected and performed as widely known in the art, and the carrier and the preparation may be prepared according to the methods described in Remington's Pharmaceutical Science latest edition.
  • the dosage and administration time may be dependent on age, sex, type of disease, status of disease, body weight, administration route, administration frequency, and type of drug.
  • the daily dosage is about 0.1 mg/kg to about 1,000 mg/kg, preferably about 1 mg/kg to about 100 mg/kg.
  • the dosage may be appropriately increased and decreased according to type of disease, progress of disease, administration route, sex, age, body weight and the like.
  • the pharmaceutical composition according to the present invention as an effective ingredient may be arbitrarily administered several times such the total daily dosage is about 0.1 mg/kg to about 1,000 mg/kg as a compound based on an adult.
  • the dosage may be appropriately increased and decreased according to type of disease, progress of disease, administration route, sex, age, body weight, health status, and the like.
  • the pharmaceutical composition according to the present invention may contain the compound of Formula (I') in an amount of about 0.0001 wt% to about 10 wt%, preferably about 0.001 wt% to about 1 wt% based on a total weight of the entire composition.
  • reagents used in the following Preparation Examples and Examples are reagent-graded from Sigma-Aldrich Co., Ltd., unless otherwise indicated.
  • the glabridin obtained in Preparation Example 1 was subjected to hydrogenation reaction in accordance with the document ( Archives of Pharmacal Research 32 (2009) 647 ⁇ 654 ) to obtain 3",4"-dihydroglabridin (Compound 1).
  • 5-hydroxy-2,2-dimethyl-2 H -chromen-6-carbaldehyde was prepared in accordance with the method of [ Tetrahedron, 57 (2001), 5335-5338 ], and then 2.04 g (10.0 mmol) of the compound was dissolved in 20 ml of CH 2 Cl 2 , and the resulting solution was stirred at room temperature for 5 hours while 1 ml of TEA and 1.54 g (11.0 mmol) of benzoyl chloride were added thereto. 10 ml of a NaHCO 3 saturated aqueous solution was added thereto, the resulting solution was stirred for another 10 min, and an aqueous layer and an organic layer were separated.
  • the separated aqueous layer was further extracted using 10 ml of CH 2 Cl 2 , the extract was combined with the organic layer, the resulting mixture was combined with the organic layer and treated with MgSO 4 and filtered, and the filtrate was concentrated.
  • the solid thus concentrated was recrystallized using isopropyl alcohol (IPA) to obtain 2.51 g (8.1 mmol) of pure 6-formyl-2,2-dimethyl-2 H -chromen-5-yl benzoate.
  • IPA isopropyl alcohol
  • the concentrate was subjected to chromatography to obtain 3.89 g (16.2 mmol) of 2'-benzyloxy-4'-methylacetophenone.
  • 3 ml of HClO 4 was added to a solution obtained by well dissolving the obtained product in 20 ml of methanol, and the ingredients were well mixed with each other at room temperature.
  • 7.33 g (16.5 mmol) of thallium nitrate (Tl(NO 3 ) 3 • 3H 2 O) was added dropwise thereto for 30 minutes while the reaction solution thus prepared was vigorously stirred at room temperature, and then the resulting mixture was further stirred at room temperature for 1 hour.
  • the organic layer was separated and concentrated, and again dissolved in 150 ml of CH 2 Cl 2 , and 25 ml of a 15% aqueous NaOH solution and 3.0 g of tetrabutylammonium bromide were added thereto. 18.82 g (110.0mmol) of benzyl bromide was added thereto while the reaction solution was vigorously stirred, and the resulting solution was refluxed overnight under vigorous stirring.
  • the reaction solution was separated into each layer and the aqueous layer was once extracted using 50 ml of CH 2 Cl 2 , and then the CH 2 Cl 2 layer was collected into one mixture, and the mixture was primarily distilled under reduced pressure for concentration.
  • the concentrate was distilled under high vacuum (about 155°C/0.01 mmHg to about 160°C/0.01 mmHg) to obtain 18.70 g (73.6 mmol) of 2'-benzyloxy-4'-ethylacetophenone.
  • 15ml of HClO 4 was added to a solution obtained by well dissolving the obtained product in 10ml of methanol, and the ingredients were well mixed with each other at room temperature.
  • 33.33 g (75.0 mmol) of Tl(NO 3 ) 3 • 3H 2 O was slowly added dropwise thereto for 60 minutes while the reaction solution thus prepared was vigorously stirred at room temperature, and then the resulting mixture was further stirred at room temperature for 5 hours.
  • the concentrate was subjected to column chromatography to obtain 4.27 g (15.8 mmol) of 2'-benzyloxy-4'-methylacetophenone.
  • a mixture of the aforementioned product, 1.76 g (20.0 mmol) of morpholine, and 1.5 g of sulfur was again vigorously stirred at 160°C overnight.
  • the reaction solution was cooled to room temperature, and then subjected to silica gel column chromatography as it is to obtain 4.24 g (11.4 mmol) of 2-(2-benzyloxy)-4-methoxyphenyl)-1-morpholinoethanethione.
  • the aforementioned product was added to 30 ml of a saturated ethanol solution, the resulting solution was refluxed for 8 hours, and then concentrated hydrochloric acid was slowly added while the resulting mixture was cooled to 0°C to adjust the pH to 1 or less.
  • a solid product obtained by distilling the mixture under reduced pressure for concentration was dissolved using 30 ml of CH 2 Cl 2 and 20 ml of water, and then the resulting mixture was separated into each other. The aqueous layer was further extracted using 30 ml of CH 2 Cl 2 , collected into one mixture, and concentrated. 20 ml of methanol was added to dissolve the concentrated solid product, and the resulting solution was refluxed for 10 hours while 1 ml of concentrated sulfuric acid was added thereto.
  • the reaction solution was dissolved in 30 ml of CH 2 Cl 2 , washed with brine, concentrated, and then purified using silica gel chromatography to obtain (methyl 2-benzyloxy-4-methoxyphenyl) acetate.
  • 6-formyl-2,2-diethyl-2 H -chromen -5-yl benzoate was obtained in the same manner as in Preparation Example 3, except that 3-ethylpent-2-enal was used instead of 3-methylcrotonaldehyde in the process of synthesizing 5-hydroxy-2,2-dimethyl-2H-chromen-6-carbaldehyde in accordance with the method of Document [ Tetrahedron, 57 (2001), 5335-5338 ] referenced in Preparation Example 3.
  • the sequence may be changed if necessary.
  • the protecting group is benzyl or substituted benzyl, it is not necessary to distinguish a separate process from the process because the hydrogen reaction and the deprotecting process are simultaneously carried out.
  • a 3-necked round flask was cooled to -78°C under nitrogen atmosphere in a dry ice-acetone bath.
  • 45 ml of a 1.0 M lithium diisopropylamide (LDA) in THF solution was added thereto, and then a solution obtained by dissolving 6.30 g (30.0 mmol) of (methyl 2-methoxymethoxy phenyl) acetate prepared in Preparation Example 4 in 100 ml of THF was slowly added thereto for 30 minutes, and further stirred for 30 minutes.
  • LDA lithium diisopropylamide
  • Methyl 2-(2-benzyloxy-4-ethylphenyl)-3-(2,2-dimethyl-5-hydroxy-2 H -1-benzopyran-6-yl) acrylate was obtained in the same manner as in Example 2(1), except that (methyl 2-benzyloxy-4-ethylphenyl) acetate prepared in Preparation Example 6 was used instead of (methyl 2-benzyloxy-4-methylphenyl) acetate.
  • Methyl 2-(2-benzyloxy-4-propylphenyl)-3-(2,2-dimethyl-5-hydroxy-2H-1-benzopyran-6-yl) acrylate was obtained in the same manner as in Example 2(1), except that (methyl 2-benzyloxy-4-propylphenyl) acetate prepared in Preparation Example 7 was used instead of (methyl 2-benzyloxy-4-methylphenyl) acetate.
  • Methyl 2-(2-benzyloxy-4-butylphenyl)-3-(2,2-dimethyl-5-hydroxy-2H-1-benzopyran-6-yl) acrylate was obtained in the same manner as in Example 2(1), except that (methyl 2-benzyloxy-4-butylphenyl) acetate prepared in Preparation Example 8 was used instead of (methyl 2-benzyloxy-4-methylphenyl) acetate.
  • Methyl 2-(2-benzyloxy-4-methoxyphenyl)-3-(2,2-dimethyl-5-hydroxy-2 H -1-benzopyran-6-yl) acrylate was obtained in the same manner as in Example 2(1), except that methyl (2-benzyloxy-4-methoxylphenyl) acetate prepared in Preparation Example 10 was used instead of (methyl 2-benzyloxy-4-methylphenyl) acetate.
  • Methyl 2-(2-benzyloxy-4-propoxyphenyl)-3-(2,2-dimethyl-5-hydroxy-2H-1-benzopyran-6-yl) acrylate was obtained in the same manner as in Example 2(1), except that methyl (2-benzyloxy-4-propoxyphenyl) acetate prepared in Preparation Example 12 was used instead of (methyl 2-benzyloxy-4-methylphenyl) acetate.
  • Methyl 2-(2-benzyloxy-4-methoxyphenyl)-3-(2,2-diethyl-5-hydroxy-2 H- 1-benzopyran-6-yl) acrylate was obtained in the same manner as in Example 2, except that methyl (2-benzyloxy-4-methoxylphenyl) acetate prepared in Preparation Example 10 was used instead of (methyl 2-benzyloxy-4-methylphenyl) acetate, and 6-formyl-2,2-diethyl-2 H -chromen-5-yl benzoate prepared in Preparation Example 14 was used instead of 6-formyl-2,2-dimethyl-2 H -chromen-5-yl benzoate.
  • the degrees of inhibition (IC 50 The half maximal inhibitory concentration) of glabridin, and compounds of Preparation Example 2 (Compound 1), Example 2 (Compound 3), Example 3 (Compound 4), Example 4 (Compound 5), Example 13 (Compound 14), Example 14 (Compound 15), Example 15 (Compound 16), Example 17 (Compound 18), Example 18 (Compound 19) and Example 20 (Compound 21) were compared to each other.
  • the degree of inhibition activity for PTP1B was investigated by using 2 mM p-nitrophenyl phosphate (p-NPP) as a substrate to measure the dephosphorylation degree.
  • p-NPP 2 mM p-nitrophenyl phosphate
  • PTP1B diluted with distilled water was reacted with 2 mM p-nitrophenyl phosphate ⁇ p-NPP, 0.1 M NaCl, 1 mM EDTA, 50 mM citrate pH 6.0, and 1 mM dithiothreitol (DTT) ⁇ and Compound 1 at various concentrations at 30°C for 30 minutes, and then the reaction was terminated with a 1 N-sodium hydroxide (NaOH) solution.
  • NaOH N-sodium hydroxide
  • the sample thus prepared was administered through oral gavage using a disposable plastic syringe once daily for 28 days (4 weeks).
  • the body weight was measured twice a week while the DIO mice were bred in this manner.
  • the anti-obesity effect (%) was calculated according to the equation defined as follows.
  • Anti-Obesity Effect ⁇ (Body weight of control group) - (Body weight of experimental group) ⁇ / (Body weight of control group) ⁇ 100
  • the compound (Compound 15) of Example 14 of the present invention was compared with the existing Rosiglytazone and Metformin which were used or are currently used as a therapeutic agent for diabetes.
  • the C 2 C 12 cell was cultured in a Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (120 unit/mL), and streptomycin (75 ⁇ g/mL), the medium used for differentiation was a DMEM medium supplemented with 1% horse serum, and the C 2 C 12 cell was cultured in the DMEM medium for 4 days.
  • DMEM Dulbecco's modified eagle medium
  • FBS fetal bovine serum
  • penicillin 120 unit/mL
  • streptomycin 75 ⁇ g/mL
  • the medium used for differentiation was a DMEM medium supplemented with 1% horse serum
  • the C 2 C 12 cell was cultured in the DMEM medium for 4 days.
  • the cell thus cultured was treated with Compound 15 in a low-glucose, serum-free medium supplemented with 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-d-glucose (2-NBDG) for 24 hours to measure the glucose absorbance at an excitation wavelength of 485 nm and an emission wavelength of 535 nm using a fluorescent detector.
  • 2-NBDG 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-d-glucose
  • Compound 15 has a capacity of promoting glucose uptake better than that of the existing therapeutic agent for diabetes.
  • the glycosylated hemoglobin(HbA1c) was measured while the db / db mice were bred.
  • the gyclosylated hemoglobin was measured at 2 days prior to group separation, 4 weeks after administration, and 6 weeks after administration, and was measured by fasting the mice for 4 hours on the measurement date, collecting blood from the caudal vein before each material was administered, and using a device for measuring glycosylated hemoglobin (SD A1cCare, SD Biosensor, Inc., Korea). The results thus measured are shown in the following Table 5.
  • the pyranochromenylphenol derivatives according to the present invention controlled blood glucose level to a nearly normal range (normal range: HbA1c 6.0 or less).
  • FIGS. 2 to 5 The microscope photographs ( FIGS. 2a , 3a , 4a and 5a ) of the case in which Compound 16 had been administered were shown, and the photographs ( FIGS. 2b , 3b , 4b and 5b ) of a control group to which no drug was administered.
  • FIG. 2a is a microscope photograph (100 times magnification) of a liver tissue stained with hematoxylin and eosin (H&E), which was collected from a mouse to which Compound 16 of the present invention had been administered for 6 weeks, and which was finally sacrificed and autopsied.
  • FIG. 2b is a microscope photograph of a control group to which Compound 16 was not administered.
  • FIG. 3a is a microscope photograph (200 times magnification) of a liver tissue stained with hematoxylin and eosin (H&E), which was collected from a mouse to which Compound 16 of the present invention had been administered for 6 weeks, and which was finally sacrificed and autopsied.
  • FIG. 2a is a microscope photograph (100 times magnification) of a liver tissue stained with hematoxylin and eosin (H&E), which was collected from a mouse to which Compound 16 of the present invention had been administered for 6 weeks, and which was finally sacrificed and autopsied.
  • FIG. 3b is a microscope photograph of a control group to which Compound 16 was not administered.
  • FIG. 4a is a microscope photograph (100 times magnification) of a liver tissue stained with perilipin antibody, which was collected from a mouse to which Compound 16 of the present invention had been administered for 6 weeks, and which was finally sacrificed and autopsied.
  • FIG. 4b is a microscope photograph of a control to which Compound 16 was not administered.
  • FIG. 5a is a microscope photograph (200 times magnification) of a liver tissue stained with perilipin antibody, which was collected from a mouse to which Compound 16 of the present invention had been administered for 6 weeks, and which was finally sacrificed and autopsied.
  • liver tissues from mice to which Compound 16 had been administered had small and compact adipocytes, so that the mice are generally healthy.
  • BV2 microglia cells were cultured at a concentration of 1 x 10 4 cells/well in a 96 well plate for 24 hours, and subjected to pre-treatment with a compound at Concentration 3 (in the case of glabridin, at a concentration of 5 uM, 10 um, and 20 uM, and in the case of Compound 4, Compound 5, Compound 15, Compound 16, and Compound 18, at a concentration of 2.5 uM, 5 uM and 10 uM) which does not suppress the cells from proliferating for 3 hours.
  • a compound at Concentration 3 in the case of glabridin, at a concentration of 5 uM, 10 um, and 20 uM, and in the case of Compound 4, Compound 5, Compound 15, Compound 16, and Compound 18, at a concentration of 2.5 uM, 5 uM and 10 uM
  • MTT Sigma, M21278
  • BV2 microglia cells were cultured at a level of 5 ⁇ 10 5 cells/well in a 24 well plate for 24 hours, the medium was removed after 24 hours, the cells were subjected to pre-treatment with the compound at Concentration 3 (in the case of glabridin, at a concentration of 5 uM, 10 um, and 20 uM, and in the case of Compound 4, Compound 5, Compound 15, Compound 16, and Compound 18, at a concentration of 2.5 uM, 5 uM and 10 uM) which does not suppress the cells from proliferating for 3 hours, and then treated with LPS (1 ⁇ g/ml), and after 24 hours, the amount of NO secreted from the cells to the medium was reacted using Griess reagent (0.1% (w/v) N-(1-naphathyl)-ethylenediamine and 1%(w/v) sulfanilamide in 5% (v/v) phosphoric acid).
  • RAW264.7 macrophages were cultured at a concentration of 1 x 10 4 cells/well in a 96 well plate for 24 hours, and subjected to pre-treatment with a compound at three concentrations (in the case of glabridin, at a concentration of 10 uM, 20 uM, and 40 uM, and in the case of Compound 4, Compound 5, Compound 15, Compound 16, and Compound 18, at a concentration of 5 uM, 10 uM and 20 uM) which does not suppress cells from proliferating for 3 hours.
  • the MTT Sigma, M21278
  • RAW264.7 macrophages were cultured at a level of 5 ⁇ 10 5 cells/well in a 24 well plate for 24 hours, the medium was removed after 24 hours, the cells were subjected to pre-treatment with the compound at three concentrations (in the case of glabridin, at a concentration of 10 uM, 20 uM, and 40 uM, and in the case of Compound 4, Compound 5, Compound 15, Compound 16, and Compound 18, at a concentration of 5 uM, 10 uM and 20 uM) which does not suppress the cells from proliferating for 3 hours, and then treated with LPS (1 ⁇ g/ml), and after 24 hours, the amount of NO secreted from the cells to the medium was reacted using Griess reagent (0.1% (w/v) N-(1-naphathyl)-ethylenediamine and 1%(w/v) sulfanilamide in 5% (v/v) phosphoric acid).
  • Example 14 The relative chemical stability of glabridin of Preparation Example 1, Example 3 (Compound 4), Example 4 (Compound 5) and Example 14 (Compound 15) were compared with each other. That is, 50 mg of each of glabridin, Compound 4, Compound 5, and Compound 15 was exactly weighed, dissolved in 50 ml of 1% HCl in MeOH and 10 ml of 1% NaOH in MeOH, and the concentrations of the compounds were examined by HPLC at each time level of 0, 8 hrs, 12 hrs, 24 hrs, 48 hrs, and 72 hrs. At this time, the concentrations of the compounds remaining in 1% HCl in MeOH and 1% NaOH in MeOH were determined using an internal standard (Compound 14 of Example 13).
  • the concentrations of the compounds remaining in 1% HCl in MeOH and 1% NaOH in MeOH at each time level are in the following Table 8 and FIG. 7 and the following Table 9 and FIG. 8 , respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP14873860.2A 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease Active EP3098224B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL14873860T PL3098224T3 (pl) 2013-12-24 2014-12-23 Pochodna piranochromenylofenolu i kompozycja farmaceutyczna do leczenia zespołu metabolicznego lub choroby zapalnej
HRP20190573TT HRP20190573T1 (hr) 2013-12-24 2019-03-25 Piranokromenil fenol derivat, i farmaceutska kompozicija za liječenje metaboličkog sindroma ili inflamatorne bolesti

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130162909 2013-12-24
KR1020140181951A KR102344479B1 (ko) 2013-12-24 2014-12-17 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
PCT/KR2014/012688 WO2015099392A1 (ko) 2013-12-24 2014-12-23 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Publications (3)

Publication Number Publication Date
EP3098224A1 EP3098224A1 (en) 2016-11-30
EP3098224A4 EP3098224A4 (en) 2017-07-05
EP3098224B1 true EP3098224B1 (en) 2019-01-30

Family

ID=53788040

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14873860.2A Active EP3098224B1 (en) 2013-12-24 2014-12-23 Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease

Country Status (20)

Country Link
US (1) US9783551B2 (hr)
EP (1) EP3098224B1 (hr)
JP (2) JP6620096B2 (hr)
KR (1) KR102344479B1 (hr)
CN (1) CN105849111B (hr)
AU (1) AU2014370697B2 (hr)
CA (1) CA2929001C (hr)
CY (1) CY1121554T1 (hr)
DK (1) DK3098224T3 (hr)
ES (1) ES2718878T3 (hr)
HR (1) HRP20190573T1 (hr)
HU (1) HUE043902T2 (hr)
IL (1) IL245908B (hr)
MX (1) MX2016008429A (hr)
NZ (1) NZ720328A (hr)
PL (1) PL3098224T3 (hr)
PT (1) PT3098224T (hr)
SG (1) SG11201604371PA (hr)
TW (1) TWI585093B (hr)
WO (1) WO2015099392A1 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
MX2018016361A (es) * 2016-06-29 2019-09-16 Glaceum Inc Derivado de piranocromenil fenol opticamente activo y composición farmacéutica que comprende el mismo.
TWI641610B (zh) * 2016-10-04 2018-11-21 南韓商格雷森伍股份有限公司 用於合成3-苯基-2,3,4,8,9,10-六氫吡喃並[2,3-f]色烯衍生物及其光學異構物的方法
TWI804600B (zh) * 2018-04-03 2023-06-11 南韓商格雷森伍股份有限公司 3-苯基-2,8-二氫吡喃[2,3-ƒ]苯并哌喃衍生物的合成方法
KR20190116099A (ko) 2018-04-03 2019-10-14 주식회사 글라세움 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물
KR20200105198A (ko) * 2019-02-28 2020-09-07 주식회사 글라세움 신경계 질환의 예방 또는 치료용 약학적 조성물
KR20210014521A (ko) 2019-07-30 2021-02-09 주식회사 글라세움 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법
WO2022260435A1 (ko) 2021-06-08 2022-12-15 주식회사 글라세움 퇴행성 안질환의 예방 또는 치료용 약학적 조성물
CN113616548B (zh) * 2021-09-02 2023-04-28 河南科技大学 一种水溶性光甘草定包合物及其制备方法
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2460134A1 (en) 2001-10-11 2003-05-08 Kaneka Corporation Peroxisome proliferator activated receptor ligand and process for producing the same
KR100565423B1 (ko) * 2003-10-20 2006-03-30 빅 바이오 주식회사 이소플라반 유도체 또는 이소플라벤 유도체의 제조방법
JP2006008604A (ja) * 2004-06-25 2006-01-12 Kuraray Co Ltd イソフラバン誘導体の製造方法
WO2007058480A1 (en) 2005-11-16 2007-05-24 Md Bioalpha Co., Ltd. Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
JP2017501163A (ja) 2017-01-12
AU2014370697A1 (en) 2016-06-16
ES2718878T3 (es) 2019-07-05
CN105849111B (zh) 2018-05-04
IL245908A0 (en) 2016-08-02
MX2016008429A (es) 2017-02-23
SG11201604371PA (en) 2016-07-28
JP2018135343A (ja) 2018-08-30
HUE043902T2 (hu) 2019-10-28
US9783551B2 (en) 2017-10-10
EP3098224A1 (en) 2016-11-30
PT3098224T (pt) 2019-04-26
NZ720328A (en) 2018-02-23
CN105849111A (zh) 2016-08-10
DK3098224T3 (da) 2019-05-13
CA2929001C (en) 2018-02-20
EP3098224A4 (en) 2017-07-05
CY1121554T1 (el) 2020-05-29
KR102344479B1 (ko) 2021-12-29
TWI585093B (zh) 2017-06-01
US20160272650A1 (en) 2016-09-22
JP6620096B2 (ja) 2019-12-11
TW201607949A (zh) 2016-03-01
IL245908B (en) 2020-08-31
AU2014370697B2 (en) 2017-01-19
WO2015099392A1 (ko) 2015-07-02
PL3098224T3 (pl) 2019-07-31
CA2929001A1 (en) 2015-07-02
HRP20190573T1 (hr) 2019-05-17
KR20150075030A (ko) 2015-07-02

Similar Documents

Publication Publication Date Title
EP3098224B1 (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
JP2022009680A (ja) 肝毒性および脂肪性肝疾患の処置に有効な化合物およびその使用
US20130296613A1 (en) Process for production of hydroxystilbene derivative having physiological activity
JP7036871B2 (ja) 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物
KR20080027191A (ko) 신규한 벤즈옥사졸 유도체, 이의 제조방법 및 이를포함하는 약학 조성물
US11643405B2 (en) Compound for treatment or prevention of liver diseases
EP4119165A1 (en) Novel 3,5-diaminobenzoic acid compound, and pin1 inhibitor and therapeutic agent for inflammatory diseases using same
CN108904481B (zh) 邻羟基查尔酮类似物在制备抗氧化药物中的应用
BR112016011281B1 (pt) Composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste e composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável deste
JP5962399B2 (ja) 代謝促進剤組成物
TW200529807A (en) Remedy
NZ749461B (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
KR20180094714A (ko) 6,7-이치환된 3-(2-히드록시페닐)크로만 유도체 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170608

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 497/04 20060101ALI20170601BHEP

Ipc: A61K 31/353 20060101ALI20170601BHEP

Ipc: C07D 493/04 20060101AFI20170601BHEP

Ipc: A61P 3/00 20060101ALI20170601BHEP

Ipc: A61P 29/00 20060101ALI20170601BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180816

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1093166

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014040598

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH, CH

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20190573

Country of ref document: HR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3098224

Country of ref document: PT

Date of ref document: 20190426

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190402

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190506

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20190573

Country of ref document: HR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2718878

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20190705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190401183

Country of ref document: GR

Effective date: 20190620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190530

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190430

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E043902

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014040598

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190573

Country of ref document: HR

Payment date: 20191125

Year of fee payment: 6

26N No opposition filed

Effective date: 20191031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190573

Country of ref document: HR

Payment date: 20201117

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190573

Country of ref document: HR

Payment date: 20211027

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190130

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1093166

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190130

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190573

Country of ref document: HR

Payment date: 20221114

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231110

Year of fee payment: 10

Ref country code: LU

Payment date: 20231110

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20190573

Country of ref document: HR

Payment date: 20231113

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231228

Year of fee payment: 10

Ref country code: GB

Payment date: 20231110

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231110

Year of fee payment: 10

Ref country code: PT

Payment date: 20231110

Year of fee payment: 10

Ref country code: NO

Payment date: 20231113

Year of fee payment: 10

Ref country code: IT

Payment date: 20231114

Year of fee payment: 10

Ref country code: IE

Payment date: 20231110

Year of fee payment: 10

Ref country code: HR

Payment date: 20231113

Year of fee payment: 10

Ref country code: FR

Payment date: 20231110

Year of fee payment: 10

Ref country code: FI

Payment date: 20231114

Year of fee payment: 10

Ref country code: DK

Payment date: 20231110

Year of fee payment: 10

Ref country code: DE

Payment date: 20231113

Year of fee payment: 10

Ref country code: CZ

Payment date: 20231110

Year of fee payment: 10

Ref country code: CY

Payment date: 20231114

Year of fee payment: 10

Ref country code: AT

Payment date: 20231114

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231114

Year of fee payment: 10

Ref country code: BE

Payment date: 20231110

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240102

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20240109

Year of fee payment: 10

Ref country code: CH

Payment date: 20240101

Year of fee payment: 10